BioMarin's Phase 3 Trial of BMN 401 Meets Only One Primary Endpoint
BioMarin Pharmaceutical (BMRN) reported that its enzyme therapy, BMN 401, for the rare disease ENPP1 deficiency met only one out of two primary endpoints in a phase 3 trial. The drug showed statistically significant improvements but failed to meet both key goals.
Tickers: $BMRN